CLASS ACTION NOTICE: Berger Montague Advises Rocket Pharmaceuticals (RCKT) Investors to Inquire About a Securities Fraud Class Action

Stock Information for Rocket Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Rocket Pharmaceuticals Inc.

ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI(TM) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kuehn Law Encourages Investors of Rocket Pharmaceuticals, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Rocket Pharmaceuticals, Inc. to Contact Law Firm
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease
Levi & Korsinsky Reminds Rocket Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - RCKT

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.